GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc (GSK) reports that several persons discharging managerial responsibilities, including Non-Executive Chair Sir Jonathan Symonds and multiple Independent Non-Executive Directors, purchased GSK securities on September 18, 2026 on the London Stock Exchange and New York Stock Exchange.
Transactions included purchases of Ordinary Shares in London and American Depositary Shares in New York at disclosed per-share prices in single, on-market trades for each individual.
GSK plc furnished a Form 6-K to incorporate additional legal opinion exhibits into its existing Form F-3 shelf registration, together with GlaxoSmithKline Capital Inc. as co-registrant. The filing adds opinions from Cleary Gottlieb Steen & Hamilton LLP as special U.S. and English counsel to those registration statements.
GSK plc (GSK) announced an agreement to acquire full global rights to a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences. The programme is expected to enter phase I clinical trials in 2027, subject to customary closing conditions.
The TCE is designed to bind T cells while targeting two validated tumour-associated antigens, aiming for deeper and more durable responses and improved tolerability compared with existing TCEs. GSK states that this asset complements its existing multiple myeloma and broader blood cancer portfolio and builds on a prior agreement with Chimagen for a dual CD19/CD20 TCE.
Under the agreement, GSK will pay an upfront fee and may make additional success-based development and commercial milestone payments, for a total potential deal value of up to $750 million. GSK highlights external forecasts that the US TCE market for multiple myeloma could exceed $10 billion by 2032.
GSK plc (GSK) reported pivotal phase III data from the ARTEMIS-008 trial in China showing that B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) reduced the risk of death by 54% versus topotecan in relapsed small cell lung cancer after platinum-based therapy (HR 0.46; 95% CI: 0.35–0.62, p<0.0001).
Patients on Ris-Rez had median overall survival of 18.5 months compared with 10.3 months for topotecan, with consistent benefits across secondary endpoints: longer progression-free survival, higher objective response and disease control rates, and fewer grade ≥3 treatment-related adverse events. GSK holds exclusive rights outside Greater China and is running a broad global programme, including the phase III EMBOLD SCLC-301 trial with pivotal data expected next year.
GSK plc (GSK) reported positive registrational phase I/II ARROS-1 data for its ROS1 tyrosine kinase inhibitor Jideytro (zidesamtinib) in TKI‑naïve patients with advanced or metastatic ROS1‑positive non-small cell lung cancer. In 94 efficacy‑evaluable patients, Jideytro achieved a 94% objective response rate, including a 15% complete response rate, after a median follow‑up of 15.2 months. Responses appeared durable, with 94% of patients still responding at nine months and 86% at 12 months; 12‑month progression‑free survival was 90%, while median duration of response and median PFS were not yet reached.
All patients with measurable brain metastases (10/10) responded, and 70% achieved complete clearance of detectable brain tumours, with 78% maintaining intracranial response at 12 months. Treatment‑related adverse events were mostly low grade; dose reductions occurred in 11% of patients and discontinuations in 1%. GSK plans a supplemental New Drug Application in the US in 2026 to seek expansion of Jideytro’s indication to first-line ROS1‑positive NSCLC, adding to its July 2026 US approval in previously TKI‑treated patients.
GSK plc (GSK) reported that multiple senior managers and one person closely associated with a manager acquired Ordinary Shares of 31¼ pence each under the company’s Share Reward Plan. Each participant acquired 7 partnership shares and 7 matching shares, totaling 14 Ordinary Shares each at £18.0296 per share on September 9, 2026, on the London Stock Exchange.
GSK plc (GSK) reported a transaction by senior executive Maya Martinez-Davis, President, involving American Depositary Shares (ADS).
On September 8, 2026, Ms Martinez-Davis acquired 9.837 notional ADS within her GSK Executive Supplemental Savings Plan account at a price of $48.5400 per ADS on the New York Stock Exchange.
GSK plc (GSK), via its wholly owned subsidiary GlaxoSmithKline Capital Inc., is offering an aggregate $6.5 billion of senior unsecured notes in multiple U.S. dollar tranches, all fully and unconditionally guaranteed by GSK plc and ranking equally with its other senior unsecured debt.
The offering comprises fixed-rate notes maturing in 2029, 2031, 2033, 2036 and 2056 with coupons of 4.850%–6.000%, plus $500 million of floating-rate notes due 2029 paying Compounded SOFR + 0.560% reset quarterly. GSK Capital Inc. may redeem the fixed-rate notes early, subject to make-whole or par call terms, and may tax-redeem any series; the floating-rate notes are otherwise non-callable to maturity.
GSK estimates net proceeds of about $6.46 billion, to be used primarily to repay outstanding borrowings under its Acquisition Facility related to the completed Nuvalent, Inc. acquisition and for general corporate purposes, including refinancing maturing debt. The notes are expected to be listed on the New York Stock Exchange or another recognized stock exchange, though there is no assurance an active trading market will develop.
GSK plc (GSK) reports that Japan’s Ministry of Health, Labour and Welfare has approved a prefilled syringe presentation of Shingrix, its Recombinant Zoster Vaccine, for the prevention of shingles. This new ready-to-use format replaces the prior two-vial presentation and is intended to simplify and make administration more convenient for healthcare professionals.
Shingrix has been approved in Japan to prevent herpes zoster in adults aged 50 and older since 2018, and in adults aged 18 and older at increased risk since 2023. GSK states that the prefilled syringe presentation is already available in the US and is launching in Europe in 2026, with the Japanese approval based on data showing technical comparability to the existing formulation and no change in indication or dosing.
GSK plc (GSK) reports awards of Ordinary Shares under its 2025 Share Value Plan. On September 8, 2026, Victoria Whyte, SVP & Company Secretary, received an award of 10,050 Ordinary Shares at a reference price of £17.9650 per share.
On the same date, Neil Falkingham, a person closely associated with Lynn Baxter (President, Europe), also received an award of 10,050 Ordinary Shares at a reference price of £17.9650 per share under the same plan.